GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
网页1 天前 · GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults...
GSK's Respiratory Syncytial Virus Vaccine Given Together With …
网页2 天之前 · Wednesday, GSK plc (NYSE: GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory...
GSK Announces Positive Topline Data on Co-Administration of …
网页3 天之前 · GSK. Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate administration. Co-administration of the RSV and shingles adjuvanted...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
网页2023年5月3日 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
New data for AREXVY, GSK’s RSV vaccine, show potential to help …
网页2023年10月25日 · GSK plc (LSE/NYSE: GSK) today announced positive preliminary results from its phase III trial [NCT05590403] evaluating the immune response and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 50 to 59, including those at increased risk of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD ...
GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US …
网页2024年2月6日 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under priority review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease.
US FDA approves GSK’s Arexvy, the world’s first respiratory …
网页2023年5月3日 · US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time. The approval is based on data from the positive pivotal AReSVi-006 phase …
About Arexvy (respiratory syncytial virus vaccine, adjuvanted) - GSK
网页2023年6月21日 · New results from the ongoing AReSVi-006 phase III trial show vaccine efficacy against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, including in participants with underlying medical conditions; Safety and reactogenicity data were consistent with initial results from the phase III programme
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
网页2023年5月3日 · CNN — After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV – and more are on the way. On Wednesday, the US Food and Drug...
‘A good day’: FDA approves world’s first RSV vaccine - Nature
网页2023年5月3日 · The US Food and Drug Administration (FDA) has approved GSK’s vaccine against respiratory syncytial virus (RSV) for use in people aged 60 years and older. This is the first RSV vaccine to...
跳至内容